www.theguardian.com
Open in
urlscan Pro
2a04:4e42:600::367
Public Scan
URL:
https://www.theguardian.com/global-development/2024/oct/03/gamechanger-hiv-prevention-drug-to-be-made-available-cheaply-in-1...
Submission: On October 21 via api from ES — Scanned from ES
Submission: On October 21 via api from ES — Scanned from ES
Form analysis
2 forms found in the DOMhttps://www.google.co.uk/search
<form action="https://www.google.co.uk/search" class="dcr-1jjnk9d"><label for="gu-search" class="dcr-0">
<div class="dcr-6v110l">Search input </div>
</label><input type="text" id="gu-search" aria-required="true" aria-invalid="false" aria-describedby="" required="" name="q" placeholder="Search the Guardian" data-link-name="header : search" tabindex="-1"
class="selectableMenuItem dcr-qcy5wo"><label for="gu-search" class="dcr-0">
<div class="dcr-6v110l">google-search </div>
<div class="dcr-radnun"><svg width="30" viewBox="-3 -3 30 30" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
<path fill-rule="evenodd" clip-rule="evenodd"
d="M9.273 2c4.023 0 7.25 3.295 7.25 7.273a7.226 7.226 0 0 1-7.25 7.25C5.25 16.523 2 13.296 2 9.273 2 5.295 5.25 2 9.273 2m0 1.84A5.403 5.403 0 0 0 3.84 9.274c0 3 2.409 5.454 5.432 5.454 3 0 5.454-2.454 5.454-5.454 0-3.023-2.454-5.432-5.454-5.432m7.295 10.887L22 20.16 20.16 22l-5.433-5.432v-.932l.91-.909z">
</path>
</svg><span class="dcr-1p0hins">Search</span></div>
</label><button type="submit" aria-live="polite" aria-label="Search with Google" data-link-name="header : search : submit" tabindex="-1" class="dcr-1gsboxi">
<div class="src-button-space"></div><svg width="30" viewBox="-3 -3 30 30" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
<path fill-rule="evenodd" clip-rule="evenodd" d="M1 12.956h18.274l-7.167 8.575.932.932L23 12.478v-.956l-9.96-9.985-.932.932 7.166 8.575H1z"></path>
</svg>
</button><input type="hidden" name="as_sitesearch" value="www.theguardian.com"></form>
https://www.google.co.uk/search
<form action="https://www.google.co.uk/search" class="dcr-1jjnk9d"><label for="gu-search" class="dcr-0">
<div class="dcr-6v110l">Search input </div>
</label><input type="text" id="gu-search" aria-required="true" aria-invalid="false" aria-describedby="" required="" name="q" placeholder="Search the Guardian" data-link-name="header : search" tabindex="-1"
class="selectableMenuItem dcr-qcy5wo"><label for="gu-search" class="dcr-0">
<div class="dcr-6v110l">google-search </div>
<div class="dcr-radnun"><svg width="30" viewBox="-3 -3 30 30" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
<path fill-rule="evenodd" clip-rule="evenodd"
d="M9.273 2c4.023 0 7.25 3.295 7.25 7.273a7.226 7.226 0 0 1-7.25 7.25C5.25 16.523 2 13.296 2 9.273 2 5.295 5.25 2 9.273 2m0 1.84A5.403 5.403 0 0 0 3.84 9.274c0 3 2.409 5.454 5.432 5.454 3 0 5.454-2.454 5.454-5.454 0-3.023-2.454-5.432-5.454-5.432m7.295 10.887L22 20.16 20.16 22l-5.433-5.432v-.932l.91-.909z">
</path>
</svg><span class="dcr-1p0hins">Search</span></div>
</label><button type="submit" aria-live="polite" aria-label="Search with Google" data-link-name="header : search : submit" tabindex="-1" class="dcr-1gsboxi">
<div class="src-button-space"></div><svg width="30" viewBox="-3 -3 30 30" xmlns="http://www.w3.org/2000/svg" aria-hidden="true">
<path fill-rule="evenodd" clip-rule="evenodd" d="M1 12.956h18.274l-7.167 8.575.932.932L23 12.478v-.956l-9.96-9.985-.932.932 7.166 8.575H1z"></path>
</svg>
</button><input type="hidden" name="as_sitesearch" value="www.theguardian.com"></form>
Text Content
Skip to main contentSkip to navigation Close dialogue1/2Next imagePrevious imageToggle caption Skip to navigation SUPPORT THE GUARDIAN Fund independent journalism with €12 per month Support us Support us Print subscriptions Search jobs Sign in Eur * Europe edition * UK edition * US edition * Australia edition * International edition The Guardian - Back to homeThe Guardian * News * Opinion * Sport * Culture * Lifestyle Show moreHide expanded menu * News * View all News * World news * UK news * Climate crisis * Ukraine * Environment * Science * Global development * Football * Tech * Business * Obituaries * Opinion * View all Opinion * The Guardian view * Columnists * Cartoons * Opinion videos * Letters * Sport * View all Sport * Football * Cricket * Rugby union * Tennis * Cycling * F1 * Golf * US sports * Culture * View all Culture * Books * Music * TV & radio * Art & design * Film * Games * Classical * Stage * Lifestyle * View all Lifestyle * Fashion * Food * Recipes * Love & sex * Health & fitness * Home & garden * Women * Men * Family * Travel * Money Search input google-search Search * Support us * Print subscriptions * * Search jobs * Holidays * Digital Archive * Guardian Licensing * About Us * The Guardian app * Video * Podcasts * Pictures * Newsletters * Today's paper * Inside the Guardian * The Observer * Guardian Weekly * Crosswords * Wordiply * Corrections * Search input google-search Search * Search jobs * Holidays * Digital Archive * Guardian Licensing * About Us * World * UK * Climate crisis * Ukraine * Environment * Science * Global development * Football * Tech * Business * Obituaries Lenacapavir, given as a twice-yearly injection, has shown strong results for HIV prevention. Photograph: Nardus Engelbrecht/AP View image in fullscreen Lenacapavir, given as a twice-yearly injection, has shown strong results for HIV prevention. Photograph: Nardus Engelbrecht/AP Fair AccessGlobal development ‘GAMECHANGER’ HIV PREVENTION DRUG TO BE MADE AVAILABLE CHEAPLY IN 120 COUNTRIES Gilead Sciences announces deal to manufacture generic versions of lenacapavir, but critics say it excludes many countries where incidence is highest Supported by About this content Kat Lay, Global health correspondent Thu 3 Oct 2024 14.13 CESTLast modified on Mon 7 Oct 2024 11.48 CEST Share Cheaper versions of the “gamechanger” HIV prevention drug lenacapavir are to be made available in 120 low- and middle-income countries, manufacturer Gilead Sciences has announced. However, campaigners said the deal “abandons” many countries with a high HIV burden, particularly in Latin America, and urged transparency over exact pricing. Lenacapavir, given as a twice-yearly injection, has shown strong results for HIV prevention. It stopped infection in a trial involving girls and women in South Africa and Uganda, and offered almost complete protection in a second trial that mainly involved men across Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the US. Gilead has faced pressure to make lenacapavir available as soon as possible and as cheaply as possible globally. Already approved as a treatment for HIV, it is sold for $42,250 a year under the name Sunlenca in the US. Researchers say it could be profitably produced for just $40 (£30) a patient, a year. The company said it had signed agreements with six manufacturers to make and sell generic lenacapavir in 120 “high-incidence, resource-limited” countries. These are mainly lower-income countries. It said it would also bridge the gap until those manufacturers were up and running by providing Gilead-supplied product, prioritising registration in 18 countries with high HIV rates including Botswana, South Africa and Thailand. However, Dr Mohga Kamal-Yanni, policy co-lead for the People’s Medicines Alliance, criticised the decision to arrange licences directly rather than through the UN-backed Medicine Patent Pool. The agreements came with “draconian conditions” that could make it harder for people in excluded countries to get hold of the drug, she said. “Behind the seemingly large numbers of countries included in the licence, Gilead is largely abandoning upper middle-income countries, where new infections are highest, with nearly all of Latin America left out,” she said. “The countries that have been excluded can use their legal rights to overcome intellectual property restrictions with a compulsory licence. However, Gilead’s agreement prevents the six licensee companies from selling to those countries. Moreover, this route is fraught with difficulties and can face legal challenges from industry. But it is a country’s right, and should be used if necessary.” View image in fullscreen Winnie Byanyima, UNAids executive director, called for access to lenacapavir for all who would benefit. Photograph: Xinhua/Rex/Shutterstock Winnie Byanyima, UNAids executive director, said: “Lenacapavir, which requires only two injections per year, could be gamechanging – if all who would benefit can access it. “We applaud Gilead for licensing the medicine without waiting for registration, which should be the norm. We are battling a pandemic and the speed at which generic versions come to market will dictate whether this medicine can really be transformative.” HIV drug could be made for just $40 a year for every patient Read more Byanyima warned that 41% of new infections were in upper middle-income countries, and excluding them from the licences “is deeply worrying and undermines the potential of this scientific breakthrough”. She said UNAids was also still waiting for a specific price and full transparency on Gilead’s costs. The generic manufacturers are India’s Dr Reddy’s Laboratories, Emcure Pharmaceuticals and Hetero Labs, as well as US-based Viatris’ unit Mylan, Egypt’s Eva Pharma and Pakistan-based Ferozsons Laboratories. UNAids said it would also like to see agreements in countries with high HIV rates such as South Africa. Gilead said it will start filing for global regulatory approval for lenacapavir as a prevention regimen for HIV by the end of this year. Explore more on these topics * Global development * Fair Access * Aids and HIV * Drugs * news Share Reuse this content MOST VIEWED * NETWORK OF ISRAELI CITIZENS ARRESTED AFTER SPYING FOR IRAN, POLICE SAY * LIVE HARRIS AND CHENEY TALK ECONOMY, WOMEN’S HEALTH AND TRUMP IN MICHIGAN CAMPAIGN EVENT – US ELECTIONS LIVE * NORTH KOREAN ARMS MORE SIGNIFICANT THAN TROOPS IN RUSSIA’S WAR AGAINST UKRAINE * WHAT IS OKRA WATER AND IS IT GOOD FOR YOUR HEALTH? * LIVE NOTTINGHAM FOREST 1-0 CRYSTAL PALACE: PREMIER LEAGUE – AS IT HAPPENED MOST VIEWED MOST VIEWED * World * UK * Climate crisis * Ukraine * Environment * Science * Global development * Football * Tech * Business * Obituaries * News * Opinion * Sport * Culture * Lifestyle Original reporting and incisive analysis, direct from the Guardian every morning Sign up for our email * Help * Complaints & corrections * SecureDrop * Work for us * * Privacy policy * Cookie policy * Terms & conditions * Contact us * All topics * All writers * Digital newspaper archive * Tax strategy * Facebook * YouTube * Instagram * LinkedIn * X * Newsletters * Advertise with us * Search UK jobs Back to top © 2024 Guardian News & Media Limited or its affiliated companies. All rights reserved. (dcr)